Complement can be produced locally or systemically and is a major link between infection and local or systemic inflammatory diseases, such as periodontitis or sepsis, respectively. However, little is known about local mechanisms that disrupt mucosal tissue-microbe homeostasis and set the stage for unwarranted complement activation. In this regard, periodontitis represents an attractive study model, as it is readily accessible for obtaining both microbial and host tissue samples to longitudinally investigate local inflammatory mechanisms. This highly prevalent disease (>47% of US adults) is initiated by a dysbiotic microbiota, leads to inflammatory destruction of tooth-supporting bone, and adversely affects systemic health in its severe form (8.5% of US adults). Periodontitis therefore urgently requires innovative treatments. The overarching concept in Project 3 of this POl is that complement is crucially and centrally involved in the initiation and amplification of destructive local inflammation in periodontitis through cross-talk interactions with the microbiota and other inflammatory pathways;hence, it represents a prime target for therapeutic intervention. Experiments have been designed to dissect the mechanisms of complement involvement in local tissue regulation of interieukin-17, a key cytokine produced by innate and adaptive immune cells and mediating inflammation and bone loss in periodontitis (Aim 1). On the basis of preliminary studies and those to be performed in Aim 1, appropriate complement inhibitors (Core B &Project 1) will be tested for their efficacy in treating periodontal inflammation and bone loss in non-human primates (Aim 2), a disease that shares key clinical and immunohistological features with human periodontitis. Local inflammation in this model will be investigated at the clinical, histological, and cellular/molecular level in a longitudinal approach that will also include periodic sampling of the periodontal biofilm to monitor complement-dependent dysbiosis. The C5a receptor (C5aR), a crucial target of microbial immune subversion leading to dysbiosis, and C3, required for the amplification of inflammation by the dysbiotic microbiota, will serve as initial targets of therapeutic intervention. Moreover, using a panel of pathway-specific inhibitors, we will dissect the initiation mechanism(s) leading to C3 activation and other complement pathways that may contribute to disease pathogenesis. Complement-specific drugs have already undergone successful safety trials, and promising interventions established in this project have potential for rapid translation to the clinic. Our longterm objective is to apply the mechanistic insights gained from studying local complement inflammation to the treatment of local infection-driven inflammatory diseases.

Public Health Relevance

Periodontitis is a prevalent local inflammatory disease that may cause tooth loss and have an adverse impact on systemic health. The objective of this proposal is to dissect the mechanisms whereby the complement system precipitates periodontitis and apply rational therapeutic intervention in a non-human primate model using appropriate complement inhibitors. This study is also expected to facilitate the development of innovative treatment modalities for other local inflammatory diseases at mucosal sites.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
2P01AI068730-06
Application #
8627401
Study Section
Special Emphasis Panel (ZAI1-ESB-I (S1))
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
6
Fiscal Year
2014
Total Cost
$464,598
Indirect Cost
$174,224
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Lamont, Richard J; Hajishengallis, George (2015) Polymicrobial synergy and dysbiosis in inflammatory disease. Trends Mol Med 21:172-83
Rafail, Stavros; Kourtzelis, Ioannis; Foukas, Periklis G et al. (2015) Complement deficiency promotes cutaneous wound healing in mice. J Immunol 194:1285-91
Reis, Edimara S; DeAngelis, Robert A; Chen, Hui et al. (2015) Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology 220:476-82
Maekawa, Tomoki; Krauss, Jennifer L; Abe, Toshiharu et al. (2014) Porphyromonas gingivalis manipulates complement and TLR signaling to uncouple bacterial clearance from inflammation and promote dysbiosis. Cell Host Microbe 15:768-78
Klapper, Yvonne; Hamad, Osama A; Teramura, Yuji et al. (2014) Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. Biomaterials 35:3688-96
Huang, Yijun; Reis, Edimara S; Knerr, Patrick J et al. (2014) Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin. ChemMedChem 9:2223-6
Pio, Ruben; Corrales, Leticia; Lambris, John D (2014) The role of complement in tumor growth. Adv Exp Med Biol 772:229-62
Maekawa, Tomoki; Abe, Toshiharu; Hajishengallis, Evlambia et al. (2014) Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis. J Immunol 192:6020-7
Mastellos, Dimitrios C; Ricklin, Daniel; Yancopoulou, Despina et al. (2014) Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Rev Hematol 7:583-98
Clarkson, Benjamin D S; Ling, Changying; Shi, Yejie et al. (2014) T cell-derived interleukin (IL)-21 promotes brain injury following stroke in mice. J Exp Med 211:595-604

Showing the most recent 10 out of 130 publications